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Abstract
Kappa Myeloma Antigen (KMA) is a plasma membrane associated form of free 
immunoglobulin kappa light chain (FkLC) expressed on malignant B cells from patients 
with multiple myeloma (MM), Waldenstrom’s macroglobulinaema (WM) and non- 
Hodgkin’s lymphoma (Walker et al. 1985). KMA is recognized by the murine monoclonal 
antibody (mAb) mKap, and its human-mouse chimeric equivalent, cKap, which is currently 
undergoing clinical trials as a therapy for kappa type MM (Boux et al. 1983; Raison et al. 
2005).
Earlier expression studies on KMA suggested that the antigen is not expressed by normal B 
cells in vivo. However, in vitro activation of tonsillar B cells induced expression of KMA 
on a subset of cells. Like their KMA expressing malignant counterparts, these were 
presumed to be FkLC secreting plasma cells or plasmablasts but, due to the lack of B cell 
lineage specific markers at the time, these cells were not phenotyped (Walker et al. 1985). 
Furthermore, given the extremely low frequency of plasmablasts and plasma cells in 
normal tissues, it was not possible to exclude the presence of a ‘normal’ KMA positive cell 
population in vivo.
The first section of this thesis expands upon this earlier work. By utilizing in vitro 
activation protocols on peripheral blood CD 19+ B cells, KMA expression was induced on a 
subset of cells. Phenotypic analysis revealed that the majority of KMA positive cells were 
CD27++ CD38+/- plasmablasts and CD38++ plasma cells. Analysis from normal human 
tissues found that a subset of plasma cells in the tonsils expressed the antigen. These cells 
co-expressed CD45, indicating that they are at an immature stage of plasma cell 
differentiation. In contrast, peripheral plasma cells, considered to be more fully mature cells 
in transit from secondary lymphoid organs to plasma cell niches in bone marrow or spleen, 
did not express KMA. This implies that KMA expression, in vivo, is limited to a small 
subset of immature plasma cells in secondary lymphoid organs such as the tonsils.
1
Despite cKap’s current assessment in clinical trials for the treatment of MM, very little is 
known about its molecular target KMA. Previous studies have showed that KMA is 
comprised of FkLC (Goodnow and Raison 1985); however it was never determined as to 
how FkLC is associated with the plasma membrane. Since FkLC is a secreted molecule, it 
was initially presumed that it associated with a proteinaceous ‘membrane receptor’ 
(Goodnow and Raison 1985). However membrane extraction studies, as described in the 
second part of this thesis, reveal that FkLC directly associates with the plasma membrane 
through a combination of hydrophobic and electrostatic forces to form KMA. Further 
investigations confirmed that FkLCs can bind directly to cellular and artificial membranes. 
Moreover, this binding is likely dependent on self-association processes, which suggest that 
KMA consists of aggregated, membrane associated FkLCs.
Lipid binding studies revealed that FkLCs associate specifically with saturated 
phosphocholine species such as sphingomyelin in membranes, and KMA expression was 
positively correlated with sphingomyelin expression in FkLC secreting cell lines.
The final section of this thesis examines how FkLCs might interact with saturated 
phosphocholine lipids. Molecular modeling of dimeric FkLC suggests they are able to 
weakly associate with phosphocholine in the conventional antigen binding pocket formed 
by the kLC variable domain (V-domain). Since FkLC aggregation is a feature of KMA, 
then the avidity effects of multi-valent binding likely increases the strength of the proposed 
FicLC-phosphocholine interaction. This hypothesis explains the observation of both 
electrostatic and hydrophobic interactions by FkLC, as KMA, with the plasma membrane - 
the electrostatic component, governed by single FkLC molecules interacting with the 
charged phosphocholine headgroups, and the hydrophobic component, due to self­
association of adjacent FkLC molecules.
Finally, a model of KMA expression by FkLC secreting cells is proposed. FkLC is 
synthesized in the endoplasmic reticulum (ER) then transported to the golgi-apparatus and 
encapsulated into vesicles destined for secretion. There FkLCs interact with saturated
2
phosphocholine lipids, such as sphingomyelin, and undergo aggregation resulting in stable 
association on the inner vesicular membrane. Fusion of the vesicle with the plasma 
membrane during exocytosis allows for membrane associated FkLC to become exposed on 
the extracellular face as KMA.
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